Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept

Nicole Shonka, Yuji Piao, Mark Gilbert, Alfred Yung, Susan Chang, Lisa M. Deangelis, Andrew B. Lassman, Jun Liu, Timothy Cloughesy, H. Ian Robins, Rita Lloyd, Alice Chen, Michael Prados, Patrick Y. Wen, John Heymach, John De Groot

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Plasma profiling of patients treated with antiangiogenic agents may identify markers that correlate with toxicity. Objectives were to correlate changes in cytokine and angiogenic factors as potential markers of toxicity to aflibercept. Circulating cytokine and angiogenic factors were measured in 28 patients with recurrent glioblastoma in a single-arm phase II study of aflibercept. Plasma samples were analyzed at baseline, 24 h, and 28 days using multiplex assays or ELISA. We evaluated log-transformed baseline biomarker expressions with Cox proportional hazard regression models to assess the effect of markers on any grade II-IV (Gr II-IV) toxicity, on-target toxicity (hypertension, proteinuria, thromboembolism), and fatigue. All tests were two sided with a statistical significance level of p = 0.05. Among 28 pts, there were 116 Gr II-IV events. Changes in IL-13 from baseline to 24 h predicted on-target toxicities. Increases in IL-1b, IL-6, and IL-10 at 24 h were significantly associated with fatigue. Progression-free survival was 14.9 months for patients in the all-toxicity group and 9.0 months for patients in the on-target toxicity group compared to 4.3 months for those who did not develop any Gr II-IV toxicity (p = 0.002 and p = 0.045, respectively). Toxicity from antiangiogenic therapy remains an important cause of antiangiogenic treatment discontinuation and patient morbidity. Changes in IL6, IL10, and IL13 were repeatedly correlated with toxicity. Profiling of IL-13 as a surrogate for endothelial dysfunction could individualize patients at risk during antiangiogenic therapy, as could identifying those at higher risk for fatigue using IL-6 and IL-10.

Original languageEnglish (US)
Pages (from-to)117-125
Number of pages9
JournalTargeted Oncology
Volume8
Issue number2
DOIs
StatePublished - Jun 2013

Keywords

  • Aflibercept
  • Cytokines
  • Glioblastoma
  • Toxicity
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept'. Together they form a unique fingerprint.

  • Cite this

    Shonka, N., Piao, Y., Gilbert, M., Yung, A., Chang, S., Deangelis, L. M., Lassman, A. B., Liu, J., Cloughesy, T., Robins, H. I., Lloyd, R., Chen, A., Prados, M., Wen, P. Y., Heymach, J., & De Groot, J. (2013). Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Targeted Oncology, 8(2), 117-125. https://doi.org/10.1007/s11523-013-0254-0